Early Prediction Tool to Identify the Need for Pharmacotherapy in Infants at Risk of Neonatal Abstinence Syndrome

Pharmacotherapy

Volumn 37, Issue 7, 2017, Pages 840-848

  Isemann, Barbara T ^a,b   Stoeckle, Elaina C ^b   Taleghani, Afshin A ^a,b   Mueller, Eric W ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

neonatal abstinence syndrome; opioids; withdrawal

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEONATAL ABSTINENCE SYNDROME; PREDICTION; PREDICTIVE VALUE; PRENATAL DRUG EXPOSURE; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; EARLY DIAGNOSIS; FEMALE; HEALTH SERVICE; NEWBORN; OPIATE ADDICTION; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RISK FACTOR;

ANALGESICS, OPIOID; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85021799415     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1948     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011;60:1487–92.
2. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 2012;307:1934–40.
3. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650–5.
4. Substance Abuse and Mental Health Services Administration. Results from the 2013 national survey on drug use and health: summary of national findings, NSDUH series H-48, HHS publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. Available from http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.htm#2.6 Accessed January, 2015.
5. ACOG Committee on Health Care for Underserved Women. American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119:1070–6.
6. Roberts SC, Nuru-Jeter A. Women's perspectives on screening for alcohol and drug use in prenatal care. Women's Health Issues 2010;20:193–200.
7. ACOG Committee on Ethics. Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Committee Opinion No. 633. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:1529–37.
8. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in US Neonatal ICUs. N Engl J Med 2015;372:2118–26.
9. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015;135:842–50.
10. Isemann B, Meinzen-Derr J, Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol 2011;31:25–9.
11. Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol 2011;26:412–21.
12. Binder T, Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29:80–6.
13. O'Connor AB, O'Brien L, Alto WA. Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy? J Perinat Med 2013;41:621–3.
14. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320–31.
15. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014;180:673–86.
16. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014 August;134(2):e527–34.
17. Patrick SW, Schumacher RE, Horbar JD, et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016;137(5):1–8. Available from https://doi.org/10.1542/peds.2015-3835.
18. Finnegan LP, Connaughton JF, Kron RE, Eich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1–2):141–58.
19. Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012;129:e540–60.
20. Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 2012;107(Suppl 1):45–52.
21. Rosen RS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Peds 1976;88:1044–8.
22. Kuschel CA, Austerberry L, Cornwell M, Couch R, Rowley RS. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child 2003;F390–3.
23. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. J Pediatr 2016;170:39.e1–44.e1.
24. Lucas K, Knobel RB. Implementing practice guidelines and education to improve care of infants with neonatal abstinence syndrome. Adv Neonatal Care 2012;12(1):40–5.
25. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr 1975;14(6):592–4.
26. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone exposed neonates. Am J Obstet Gynecol 2008;199:396.e1–397.e7.
27. Dashe JS, Sheffield JS, Oscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002 Dec;100(6):1244–9.
28. Gaalema DE, Heil SH, Badger GJ, Metayer JS, Johnston AM. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend 2013;133:266–9.
29. Association of State and Territorial Health Officials (ASTHO). How state health departments can use the spectrum of prevention to address neonatal abstinence syndrome. Companion Report. Arlington, VA: ASTHO; 2015. Available from http://www.astho.org/Prevention/Rx/NAS-Framework. Accessed December 7, 2016.